The Effect of Obesity and Weight Loss in Heart Failure With Preserved Ejection Fraction
Launched by UNIVERSITY OF OXFORD · May 23, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how weight loss affects people with heart failure who still have good heart function, known as heart failure with preserved ejection fraction (HFpEF), and who are overweight or obese. The main goals are to see if losing weight can improve the shape of the heart, how well it pumps blood, and how the body uses energy. Additionally, the study will look at how weight loss impacts a person's quality of life and their ability to exercise.
To be eligible for this study, participants should have HFpEF and a body mass index (BMI) of at least 27.5. If you join the trial, you will have two study visits spaced 3 to 6 months apart, during which your heart function and overall health will be assessed through various tests. Participants will be assigned by chance to either a weight loss program, where they will use meal replacement products for 8 weeks, or a control group that will continue standard care. This trial is currently recruiting individuals aged 65 to 74, regardless of gender. It's important to note that certain medical conditions or circumstances, such as pregnancy or severe heart disease, may prevent someone from participating.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Heart failure with preserved ejection fraction (HFpEF)
- • Left ventricular ejection fraction (LVEF) =/\> 50%
- • Body Mass Index (BMI) approximately =/\> 27.5 kg/m\^2
- Exclusion Criteria:
- • Contraindications to magnetic resonance imaging
- • NYHA class IV
- • Significant valvular, ischemic, infiltrative or other potentially confounding cardiac disease
- • Pregnancy, planned pregnancy or lactating
- • Any other conditions which may potentially compromise the safety or scientific validity of the study
About University Of Oxford
The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oxford, , United Kingdom
Patients applied
Trial Officials
Oliver J Rider, DPhil
Principal Investigator
University of Oxford
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported